國藥科技股份(08156.HK)與青海御騰商貿簽署商業合同 防偽業務拓展到啤酒行業
格隆匯10月27日丨國藥科技股份(08156.HK)發佈公吿,公司的間接全資附屬公司與百威英博啤酒集團的青海省經銷總代理——青海御騰商貿有限責任公司簽署商業合同,集團向其代理的啤酒產品提供國科防偽創新型防偽產品。隨着合同的簽署,國科防偽創新型防偽產品的覆蓋範圍從現有的茶葉、天然食品、美粧電商平台、健康食品拓展到啤酒行業。
國科防偽創新型防偽產品內含專利技術,主打“防偽”等四大特徵,採用全鏈路防偽體系,防偽包裝及線上防偽訊息驗證平台構成國科防偽創新型防偽產品的核心。同時國科防偽創新型防偽產品在不同的應用場景中被賦予不同的功能和屬性,令該產品改寫傳統的防偽方式內涵,吸引用户積極參與防偽驗真。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.